Back to Search
Start Over
Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
- Source :
- BMC Cancer, BMC Cancer, BioMed Central, 2018, 18 (1), pp.1100. ⟨10.1186/s12885-018-5002-5⟩, BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018), Bmc Cancer, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Publication Year :
- 2018
- Publisher :
- HAL CCSD, 2018.
-
Abstract
- Background In acute lymphoblastic leukemia (ALL), the presence of minimal residual disease (MRD) after induction/consolidation chemotherapy is a strong prognostic factor for subsequent relapse and mortality. Accordingly, European clinical guidelines and protocols recommend testing patients who achieve a complete hematological remission (CR) for MRD for the purpose of risk stratification. The aim of this study was to provide quantitative information regarding real-world clinical practice for MRD testing in five European countries. Methods A web-based survey was conducted in March/April 2017 in France, Germany, Italy, Spain, and the UK. The survey was developed after consultation with specialist clinicians and a review of published literature. Eligible clinicians (20 per country; 23 in Spain) were board-certified in hemato-oncology or hematology, had at least five years’ experience in their current role after training, had treated at least two patients with B-cell precursor ALL in the 12 months before the survey or at least five patients in the last five years, and had experience of testing for MRD in clinical practice. Results MRD testing is now standard practice in the treatment of adult ALL across the five European countries, with common use of recent treatment protocols which specify testing. Respondents estimated that, among clinicians in their country who conduct MRD testing, 73% of patients in first CR (CR1) and 63% of patients in second or later CR (CR2+) are tested for MRD. The median time point reported as most commonly used for the first MRD test, to establish risk status and to determine a treatment plan was four weeks after the start of induction therapy. The timing and frequency of tests is similar across countries. An average of four or five post-CR1 tests per patient in the 12 months after the first MRD test were reported across countries. Conclusions This comprehensive study of MRD testing patterns shows consistent practice across France, Germany, Italy, Spain, and the UK with respect to the timing and frequency of MRD testing, aligning with use of national protocols. MRD testing is used in clinical practice also in patients who reach CR2 + . Electronic supplementary material The online version of this article (10.1186/s12885-018-5002-5) contains supplementary material, which is available to authorized users.
- Subjects :
- Adult
Male
Cancer Research
Pediatrics
medicine.medical_specialty
Neoplasm, Residual
Subsequent Relapse
Cross-sectional study
Lymphoblastic Leukemia
Clinical Decision-Making
[SDV.CAN]Life Sciences [q-bio]/Cancer
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
Induction therapy
hemic and lymphatic diseases
MRD testing
Genetics
Medicine
Humans
In patient
Oncology & Carcinogenesis
Internet
business.industry
Minimal residual disease
Consolidation Chemotherapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
3. Good health
Test (assessment)
Europe
body regions
Cross-Sectional Studies
Oncology
030220 oncology & carcinogenesis
Health Care Surveys
Cross-sectional survey
Female
business
ALL
030215 immunology
Research Article
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Database :
- OpenAIRE
- Journal :
- BMC Cancer, BMC Cancer, BioMed Central, 2018, 18 (1), pp.1100. ⟨10.1186/s12885-018-5002-5⟩, BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018), Bmc Cancer, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Accession number :
- edsair.doi.dedup.....e03f846615828a350adb84177af8db1b